[Updates: phase-2b lineup for IDX899; 2010-2011 news flow; table of insider shareholdings; new version of “The New Battle Lines in HIV”; new version of “HCV: Most Likely to Succeed.”]
HIV program #msg-55627397The New Battle Lines in HIV #msg-52408979Sustiva, which IDX899 might supersede, sells $1.3B/yr #msg-35391933IDIX, GSK ink IDX899 collaboration #msg-52571933 Why investors tend to overlook IDX899 #msg-43254006 GSK/PFE launch ViiV Healthcare #msg-49507158IDIX receives $6.5M milestone from GSK (4/23/10) #msg-49743057Remaining IDX899 milestone payments from GSK #msg-55627169Phase-2b lineup for IDX899 #msg-37495719 Anticipated duration of a phase-2b trial #msg-31925486 Phase-1/2 IDX899 monotherapy data (PR) #msg-31944395 Phase-1/2 IDX899 monotherapy data (chart) #msg-46084532 IDX899 paper in Curr Opin Investigational Drugs #msg-49275972 HIV market data from GILD’s 1Q10 CC #msg-35674369 HIV market overview (2007 article from CNNMoney) #msg-34894135 Musings on Truvada’s patent status #msg-31175781 HIV incidence in US is higher than previously thought #msg-31419107 Increased HIV screening will expand market #msg-33124429 New guidelines to recommend earlier treatment (1) #msg-36745396 New guidelines to recommend earlier treatment (2) #msg-37210627 Half of untreated US carriers are in 350-500 CD4 range #msg-52730834 Phase-2b data for GSK’s ‘572 integrase inhibitor #msg-29985830 Design of a phase-3 HIV trial
HCV program: Economic rationale and competition #msg-55626750HCV: Most Likely to Succeed (IMHO) #msg-38956178 HCV market forecast from Decision Resources #msg-54346052 Bolus of 600K US patients awaiting treatment #msg-34694166 US prevalence of genotypes 1a and 1b #msg-40127105Up-front payments of HCV partnerships #msg-50280348 HCV treatment paradigms 2010-2017 #msg-54225312Who’s Who in All-oral HCV Programs #msg-36780163 Musings on combining drugs from different classes #msg-30190435 Devastating risk of undertreating HCV #msg-34925415 Interferon and the Law of Diminishing Returns #msg-34797714 Annual sales of ifn-alpha drugs
HCV program: IDX184 nucleotide polymerase inhibitor #msg-54120531FDA puts clinical hold on IDX184 and IDX320 #msg-54130390 Musings on the FDA clinical hold #msg-54120531 Final phase-2a data are very nice (scan to middle of PR) #msg-49115388Why nucleotides are better than nucleosides #msg-39719159 Phase-1b monotherapy data #msg-43046863 NVS declines to license IDX184 #msg-43102142 Musings on NVS’ decision (dewophile) #msg-49116246 Possible IDX184 interest by Roche (1) #msg-49123150 Possible IDX184 interest by Roche (2) #msg-26915921 How IDX184 is unlike NM283
HCV program: IDX320 protease inhibitor #msg-54120531FDA puts clinical hold on IDX184 and IDX320 #msg-54130390 Musings on the FDA clinical hold (1) #msg-54410072 Musings on the FDA clinical hold (2) #msg-54120531 Final phase-1b monotherapy data (scan to middle of PR) #msg-49055353 Phase-1 PK and drug-interaction data #msg-36600884 Musings on selectivity of HCV PI’s
HCV program: IDX375 non-nucleoside polymerase inhibitor #msg-54120531 Interim phase-1 data (scan to bottom) #msg-34334563 Preclinical data from 2008 AASLD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.